GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...
STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.
GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.
Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...
Pharmaceutical Technology on MSN12d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...
DPA International on MSN12d
British pharmaceutical company GSK reports drop in Q3 pre-tax profitBritish pharmaceutical company GSK reported on Wednesday that its third-quarter profit before tax dropped to £64 million ($83 ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback